ArticleExpert review of dermatology2009
Genetics and genomics of melanoma.
Article in Expert review of dermatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 56 citations in OpenAlex.
- Unveiling the Prevalence and Surgical Burden of Neurocristopathies: A Scoping Review and Statistical Analysis.Research square · 2026Article
- ATAD2 drives melanoma growth and progression and inhibits ferroptosis.EMBO reports · 2026Article
- PI3K Functions Downstream of Cdc42 to Drive Cancer phenotypes in a Melanoma Cell Line.Small GTPases · 2023 · on this mapArticle
- Validation of a Liquid Biopsy Protocol for Canine BRAFV595E Variant Detection in Dog Urine and Its Evaluation as a Diagnostic Test Complementary to Cytology.Frontiers in veterinary science · 2022Article
- Review
- SFPQ promotes an oncogenic transcriptomic state in melanoma.Oncogene · 2021Article
- Article
- TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.Cancer research · 2019Article
- Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.Bioscience reports · 2018Review
- Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.BMC cancer · 2017Article
- Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets.PloS one · 2017Article
- Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.Pathology oncology research : POR · 2015Article
- Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review.Oncology letters · 2015Article
- Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression.Translational oncology · 2015Article
- Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions.Cancer research · 2014Article
- GAB2 induces tumor angiogenesis in NRAS-driven melanoma.Oncogene · 2013Article
- Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.Nature cell biology · 2012Article
- Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.World journal of surgical oncology · 2012Article
- Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment.Nature communications · 2012Article
- Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.Oncotarget · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The rapidly increasing incidence of melanoma, coupled with its highly aggressive metastatic nature, is of urgent concern. In order to design rational therapies, it is of critical importance to identify the genetic determinants that drive melanoma formation and progression. To date, signaling cascades emanating from the EGF receptor, c-MET and other receptors are known to be altered in melanoma. Important mutations in signaling molecules, such as BRAF and N-RAS, have been identified. In this review, some of the major genetic alterations and signaling pathways involved in melanoma will be discussed. Given the great deal of genetic heterogeneity observed in melanoma, it is likely that many more genetic determinants exist. Through the use of powerful genomic technologies, it is now possible to identify these additional genetic alterations in melanoma. A critical step in this analysis will be culling bystanders from functionally important drivers, as this will highlight genetic elements that will be promising therapeutic targets. Such technologies and the important points to consider in understanding the genetics of melanoma will be reviewed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.